Related Experiment Video

Updated: Oct 6, 2025

Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer
11:31

Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer

Published on: May 20, 2016

10.9K

Thoughts and suggestions on the fact that dacomitinib reduction did not affect its efficacy in the Archer 1050 study

Jing Zhang1, Yue Ren2, Qiu Wang1

  • 1Department of Oncology, The Second People's Hospital of Yibin, No. 268, Nanguang Road, Yibin, 644000, Sichuan Province, China.

Future Oncology (London, England)
|January 20, 2022
PubMed
Abstract

No abstract available in PubMed .

Keywords:
adverse reactionsdacomitinibefficacypharmacokineticsplasma exposure concentrationside effects

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.0K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.4K

Related Concept Videos

Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
8